TITLE

Controlled-onset extended-release verapamil was not equivalent to standard therapy for preventing cardiovascular disease

PUB. DATE
November 2003
SOURCE
ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p74
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article discusses whether initial therapy with controlled-onset extended-release (COER) verapamil is equivalent to standard therapy for preventing cardiovascular disease events in patients with hypertension. Patients were stratified by site and standard care in blocks of 2, 4, or 6, and were allocated to initial treatment with COER verapamil, 180 mg or standard therapy. All patients received placebo as the alternate treatment.
ACCESSION #
11533513

 

Related Articles

  • Controlled-onset extended-release verapamil was not equivalent to standard therapy for preventing cardiovascular disease: COMMENTARY. Rosenberg, Eric; Davidson, Richard // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p74 

    The primary aim of controlled onset verapamil investigation of cardiovascular end points (COVINCE) was important to determine whether extended-release verapamil was equivalent to atenolol and hydrochlorothiazide for preventing CVD events. The investigators had planned to evaluate 16000 patients...

  • L-Type Calcium Channels. Triggle, David J. // Current Pharmaceutical Design;Feb2006, Vol. 12 Issue 4, p443 

    The Ca2+ channel blockers represent a successful group of therapeutic agents directed against cardiovascular targets, including hypertension and angina. These drugs, including the first-generation verapamil, nifedipine and diltiazem are directed against a subclass of voltage-gated Ca2+ channel -...

  • Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or nonblack patients.  // ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p63 

    This article presents information on a clinical study according to which amlodipine or lisinopril was not better than chlorthalidone for reducing cardiovascular disease (CVD) risk in hypertensive black or nonblack patients. The study explored whether in black or nonblack patients with...

  • verapamil.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1192 

    This article presents a nurse's guide to the calcium channel blocker verapamil. Verapamil is indicated for the management of hypertension, angina pectoris and/or vasospastic angina, management of supraventricular arrhythmias and rapid ventricular rates in atrial flutter or fibrillation....

  • Association of CYP3A5 Polymorphisms with Hypertension and Antihypertensive Response to Verapamil. Langaee, T. Y.; Gong, Y.; Yarandi, H. N.; Katz, D. A.; Cooper-DeHoff, R. M.; Pepine, C. J.; Johnson, J. A. // Clinical Pharmacology & Therapeutics;Mar2007, Vol. 81 Issue 3, p386 

    In the CYP3A5 gene, the A>G (*3) and G>A (*6) polymorphisms result in severely decreased expression of CYP3A5 enzyme relative to a normal functional allele (*1). We sought to determine if the CYP3A5 genetic polymorphisms were associated with level of blood pressure (BP), risk of hypertension...

  • Trandolapril delayed persistent microalbuminuria in hypertension, type 2 diabetes, and normoalbuminuria.  // ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p65 

    This article reports that trandolapril delayed persistent microalbuminuria in hypertension, type 2 diabetes, and normoalbuminuria. The study was designed on randomized placebo-controlled trial. It was found that trandolapril, alone or with verapamil, but not verapamil alone, delayed the...

  • Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Kereiakes, Dean J.; Chrysant, Steven G.; Izzo Jr., Joseph L.; Littlejohn III, Thomas; Melino, Michael; Lee, James; Fernandez, Victor; Heyrman, Reinilde // Cardiovascular Diabetology;2012, Vol. 11 Issue 1, p134 

    Background Patients with hypertension and cardiovascular disease (CVD), diabetes, or chronic kidney disease (CKD) usually require two or more antihypertensive agents to achieve blood pressure (BP) goals. Methods The efficacy/safety of olmesartan (OM) 40 mg, amlodipine besylate (AML) 10 mg, and...

  • Calcium--Channel Blockers and the Gastrointestinal Tract. Traube, Morris; McCallum, Richard W. // American Journal of Gastroenterology;Nov1984, Vol. 79 Issue 11, p892 

    Reviews the gastrointestinal activities of three calcium-channel blocking agents, and discusses their potential benefits in clinical gastroenterology. Nifedipine; Verapamil; Diltiazem.

  • Redistribution of Diltiazem in the Early Postmortem Period. Moriya, Fumio; Hashimoto, Yoshiaki // Journal of Analytical Toxicology;May/Jun2004, Vol. 28 Issue 4, p269 

    Determines the tissue distribution of the calcium channel blocker, diltiazem, after it was used to treat hypertension in two cases. Use of liquid-liquid extraction to isolate diltiazem; Comparison between the diltiazem concentration in blood in the right cardiac chambers and the right femoral...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics